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Objectives. This study sought to evaluate long-term predictors
of coronary events in men and women with arteriographically
defined coronary artery disease (CAD).
Background. There is conflicting evidence of the role of triglyc-
erides (TGs) as a prognosticator of CAD, and no studies have
examined the long-term outcome of “normal” levels in predicting
new coronary events.
Methods. This was a retrospective cohort study that evaluated
740 consecutive patients presenting for diagnostic coronary arte-
riography between 1977 and 1978. Beginning in 1988, patients
with arteriographic CAD (n 5 350) were recontacted and asked to
complete detailed medical questionnaires. Case and control pa-
tients were stratified by development of new coronary events,
including death from ischemic heart disease, nonfatal myocardial
infarction and revascularization.
Results. There were 199 events during the 18-year follow-up
period. The mean high density lipoprotein cholesterol (HDL-C)
was significantly lower (35 vs. 39 mg/dl; p 5 0.002) and TGs
higher (160 vs. 137 mg/dl; p 5 0.03) in case patients than in
control patients; After adjusting for age, gender and beta-
adrenergic blocking agent use, multiple logistic regression analy-
sis revealed the following independent predictors of CAD events:
diabetes mellitus (relative risk [RR] 2.1, 95% confidence interval
[CI] 1.4% to 3.1%), HDL-C <35 mg/dl (RR 1.5, 95% CI 1.1% to
2.0%) and TGs >100 mg/dl (RR 1.5, 95% CI 1.1% to 2.1%). A
Kaplan-Meier analysis revealed significantly reduced survival
from CAD events in patients with baseline TG levels >2100 mg/dl
compared with TG levels <100 mg/dl (p 5 0.008).
Conclusions. TG levels previously considered “normal” are
predictive of new CAD events. The cutpoints established by the
National Cholesterol Education Program for elevated TGs (>200
mg/dl) may need to be refined.
(J Am Coll Cardiol 1998;31:1252–7)
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The importance of triglycerides (TGs) as a risk factor for
coronary artery disease (CAD) has long been controversial.
The earliest study demonstrating this association nearly four
decades ago (1) was disputed several years later (2). Subse-
quently, epidemiologic and observational studies disclosed that
TG levels predicted CAD in univariate analysis but this effect
was often attenuated when other more powerful covariates
(e.g., high density lipoprotein cholesterol [HDL-C]) were
entered into the analysis (3). Recently, however, a large body
of data has revived interest in TGs. They have included the
discovery of TG-rich lipoproteins in atherosclerotic plaques
(4). In addition, TGs or hydrolyzed TG-rich lipoproteins (e.g.,
remnant particles) have been shown to predict the extent of
CAD (5) and progression of mild to moderate lesions (6,7), the
lesions most vulnerable to plaque fissuring and rupture (8).
The National Cholesterol Education Program (NCEP)
have established a cutpoint of 200 mg/dl, below which both
total cholesterol and TG levels are considered desirable (9).
For total cholesterol, this cutpoint was in part derived from the
Multiple Risk Factor Intervention Trial, owing to the marked
increase in CAD rates coinciding with a total cholesterol level
.200 mg/dl (10). Similar data are not available for TGs; the
cutpoint of 200 mg/dl appears to have arisen from modifica-
tions of a National Institutes of Health Consensus Develop-
ment Conference (11). Furthermore, the disparity between
median total cholesterol (199.8 mg/dl) and TGs (100 mg/dl) in
adult U.S. men and women (12), suggests that the level of TGs
presently viewed as “normal” or desirable, may in fact be too
high. Therefore, the purpose of the Baltimore Coronary
Observational Long-Term Study (COLTS) was to determine
whether TG levels in the desirable range may pose an addi-
tional risk of new CAD events in patients with arteriographi-
cally defined CAD.
Methods
Patient selection and baseline data. Seven hundred forty
consecutive patients were admitted for diagnostic cardiac
catheterization at The Johns Hopkins Hospital between Feb-
ruary 1977 and April 1978. They comprised a group of patients
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evaluated for coronary risk factors associated with arterio-
graphically defined CAD (13). All patients completed a de-
tailed self-administered risk factor questionnaire and fasting
blood was sampled on the morning before catheterization.
Plasma cholesterol and TG levels were determined in a
Technicon Auto Analyzer II (Technicon Instruments Corp.).
Preparative ultracentrifugation (18 h 3 105,000 g) allowed for
separation of very low density lipoprotein cholesterol from
HDL-C and low density lipoprotein cholesterol (LDL-C).
HDL-C was measured following heparin-manganese precipi-
tation of apolipoprotein B-containing lipoproteins. LDL-C was
estimated by the Friedewald equation (14). Coronary arterio-
grams were graded by three cardiologists after qualitatively
analyzing the degree of stenosis in 15 segments of the coronary
tree (15). Ventriculography was performed to evaluate left
ventricular function.
Data collection and end points. In 1988, the follow-up
study was designed. Patients were excluded if they had had a
myocardial infarction within 3 months of the baseline coronary
angiogram (16) or had received heparin before lipid or li-
poprotein measurements (17) (n 5 205). Rigorous attempts
were made to recontact the remaining 535 patients through a
variety of sources, including referring physicians, medical
records, the Motor Vehicle Agency and the Social Security
Administration. Once a patient was located, each was asked to
complete medical questionnaires detailing new cardiovascular
events and diagnostic and therapeutic interventions occurring
subsequent to the baseline (1977 to 1978) coronary arterio-
gram. End points included cardiovascular death, based on the
International Classification of Diseases, Clinical Modification
(ICD-9-CM Codes 410-411) (18); nonfatal myocardial infarc-
tion, defined by electrocardiographic and enzymatic criteria
(19); surgical revascularization (unless scheduled in concert
with the baseline coronary angiogram); percutaneous translu-
minal coronary angioplasty; and nonsurgical coronary vessel
occlusion. End points were confirmed by medical records,
death certificates (obtained through the National Death Index)
and autopsy records (where applicable). As data collection was
completed in November, 1996, a total of 18 years of follow-up
information was obtained.
Statistical analysis. Data collected at baseline were stored
in the SAS data base system and used for subsequent analysis.
Patients were grouped into those with and without new
cardiovascular events. Continuous and categorical variables
were analyzed by the Student t test and chi-square analysis,
respectively. The designated level of significance was p , 0.05.
Categoric variables for lipoproteins included low HDL-C (,35
mg/dl) and elevated LDL-C (.130 mg/dl) as outlined by the
NCEP (9). The TG cutpoint of 100 mg/dl was selected because
it approximates the median level in adult men (112 mg/dl) and
women (88 mg/dl) in the United States and Canada (12). Other
categorical variables were the number of “diseased” vessels,
defined as 50% or greater stenosis in an epicardial coronary
artery segment, left ventricular ejection fraction ,35%, pres-
ence or absence of hypertension, beta-blocker use, diabetes
mellitus, cigarette smoking, obesity (body mass index [BMI]
.27), and sedentary lifestyle.
An age- and gender-adjusted Cox proportional hazards
regression model was employed to estimate the effect of
specific covariates as independent predictors of new CAD
events. Relative risk and the corresponding 95% confidence
interval were designated for each statistically significant covari-
ate. A Kaplan-Meier survival analysis (20) assessed the time to
event rate stratified by a TG cutpoint of 100 mg/dl.
Results
Patient follow-up. Of the 535 patients meeting the initial
eligibility criteria, follow-up information was attained for 492
(92%). This report focuses on patients with arteriographic
CAD defined at baseline (n 5 350). Sixty-three percent of
women (n 5 72) and 56% of men (n 5 278) (p 5 0.3) had new
events during the 18-year follow-up period; most patients
(64%) succumbed to ischemic heart disease (Table 1).
Risk factor assessment and lipoprotein measurements.
The prevalence of selected risk factors in men and women is
shown in Table 2. There was a significantly higher prevalence
of diabetes mellitus in women and cigarette smoking in men.
Most men and women had TG levels $100 mg/dl and were
sedentary. The mean baseline levels of lipids and lipoproteins
in patients with and without new CAD events is listed in Table
3. There were significantly higher levels of TGs and lower
levels of HDL-C among patients with new events. Similarly, we
found a higher rate of diabetes mellitus and obesity (BMI .27
kg/m2) at baseline in patients having new CAD events (Table
4). The high overall rate of sedentary lifestyle and cigarette
smoking may have precluded significant differences between
the groups.
Abbreviations and Acronyms
BMI 5 body mass index
CAD 5 coronary artery disease
CI 5 confidence interval
COLTS 5 Baltimore Coronary Observational Long-Term Study
HDL-C 5 high density lipoprotein cholesterol
LDL-C 5 low density lipoprotein cholesterol
NCEP 5 National Cholesterol Education Program
RR 5 relative risk
TG 5 triglyceride
Table 1. Cardiovascular Events in the Baltimore Coronary
Observational Long-Term Study
No. of Patients
Death from ischemic heart disease (ICD-9 410–411) 136
Nonfatal myocardial infarction 20
Coronary revascularization 38
Nonsurgical vessel occlusion 5
Total 199
ICD-9 5 International Classification of Disease, Ninth Revision.
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The baseline prevalence of selected risk factors in CAD
patients with new CAD events is shown in Table 4. There was
a significantly higher prevalence of obesity and diabetes mel-
litus compared with other variables tested. We also assessed
the impact of beta-blockers, agents that commonly elevate TGs
(21). A higher prevalence of beta-blocker use was observed
with a TG level $100 mg/dl than with a TG level ,100 mg/dl
(53% vs. 49%, p 5 0.013), although beta-blocker use was not
an independent predictor of new events (see later).
Figure 1 illustrates the baseline TG quartiles in CAD
patients with new events. There was a significantly higher
prevalence of low TGs (first quartile mean ,101 mg/dl) than
high TGs (quartiles 2 to 4) in patients without new CAD events
(p 5 0.002).
Regression and survival analyses. A univariate analysis
assessed the effect of various covariates on CAD event rate.
The variables tested included beta-blocker use, BMI .27,
cigarette smoking, diabetes mellitus, HDL-C ,35 mg/dl, hy-
pertension, LDL-C .130 mg/dl, sedentary lifestyle and TG
level $100 mg/dl. Only diabetes mellitus, TG level $100 mg/dl
and HDL-C ,35 mg/dl were statistically important predictors
of new events. A Cox regression analysis adjusted for age,
gender and beta-blocker use demonstrated that diabetes mel-
litus (relative risk [RR] 2.1, 95% confidence interval [CI] 1.4%
to 3.1%), HDL-C ,35 mg/dl (RR 1.5, 95% CI 1.1% to 2.0%)
and TG level $100 mg/dl (RR 1.5, 95% CI 1.1% to 2.1%) were
independent predictors of new CAD events. Even after exclu-
sion of diabetic patients, TGs remained a significant predictor
of new CAD events (RR 1.8, 95% CI 1.2% to 2.7%). Kaplan-
Meier survival analysis (Fig. 2) demonstrated significantly
reduced survival from subsequent CAD events in patients with
a baseline TG level $100 mg/dl than in those with higher TG
levels (p 5 0.008).
Discussion
The most novel finding of this 18-year follow-up study is that
a TG level previously viewed as “normal” and within the
desirable range (100 to 199 mg/dl) predicts new CAD events in
patients with arteriographically defined CAD. The study also
extends previous observations that diabetes mellitus and low
HDL-C are independent predictors of CAD (22,23).
Mechanisms linking TG and TG-rich lipoproteins to CAD.
Previous studies may have failed to expose lower TG levels as
a potentially important source of CAD events because of the
lack of a curvilinear effect as seen with LDL-C (10). Inhibited
hydrolysis of TG-rich lipoproteins resulting in very high TG
levels (.1,000 mg/dl) has with few exceptions (24) been more
commonly associated with pancreatitis rather than CAD (25).
By contrast, partial or complete hydrolysis yields particles that
are smaller and cholesterol enriched. These remnant particles
appear to be avidly incorporated by macrophages in a manner
analogous to modified LDL-C (26). Indeed, there is increasing
Figure 1. Baseline TG quartiles in patients with CAD and new events.
Quartile 1 5 ,101 mg/dl; quartile 2 5 101 to 134 mg/dl; quartile 3 5
135 to 186 mg/dl; quartile 4 5 .187 mg/dl. Bar graph illustrates the
prevalence of each quartile in patients with CAD without new events.
Patients without a CAD event evidenced a higher prevalence of low
TGs (quartile 1) and a lower prevalence of high TGs (quartiles 2 to 4)
than did patients with a new event (p 5 0.002).
Table 3. Mean (6SD) Baseline Levels of Selected Variables With
and Without New Coronary Artery Disease Events
Variable CAD No CAD p Value
Age 54.3 6 9.5 54.1 6 8.9 NS
TC 219.0 6 41.1 216.6 6 48.4 NS
LDL-C 152.6 6 39.0 149.2 6 45.8 NS
TGs 160 6 95.6 137.2 6 101.4 0.03
HDL-C 35.2 6 8.9 38.7 6 11.3 0.002
*CAD 5 coronary artery disease; HDL-C 5 high density lipoprotein
cholesterol; LDL-C 5 low density lipoprotein cholesterol; TC 5 total choles-
terol; TGs 5 triglycerides.
Table 4. Baseline Prevalence of Selected Variables With and
Without New Coronary Artery Disease Events
Variable CAD No CAD p Value
BMI .27 kg/m2 38% 25% 0.003
Cigarette smoker 74% 70% NS
Diabetes mellitus 17% 7% 0.0002
Hypertension 38% 32% NS
Sedentary lifestyle 74% 76% NS
BMI 5 body mass index; CAD 5 coronary artery disease.
Table 2. Prevalence of Selected Risk Factors in Men and Women




(n 5 72) p Value
BMI .27 kg/m2 33% 36% NS
Cigarette smoker 80% 63% 0.003
Diabetes mellitus 12% 22% 0.024
Hypertension 36% 44% NS
Low HDL 51% 71% 0.003
Sedentary lifestyle 76% 75% NS
TGs $100 mg/dl 69% 63% NS
BMI 5 body mass index; HDL 5 high density lipoprotein; TGs 5 triglyc-
erides.
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evidence that lipoprotein lipase genetic polymorphisms or
mutations that lead to partial catabolism of TG-rich lipopro-
teins may be associated with premature CAD even in the
absence of overt hypertriglyceridemia (27–29). Enhanced
atherogenicity of TG-rich lipoproteins may also result indi-
rectly by means of increased transfer of TG to lipoproteins of
higher density (LDL-C and HDL-C) in exchange for cho-
lesteryl esters (30). Both TG-rich LDL-C and HDL-C are
avidly hydrolyzed by hepatic lipase; the consequences are a
predominant population of small, dense LDL-C particles that
are highly susceptible to oxidation (31) and cholesteryl ester
poor HDL-C that may bolster apolipoprotein A-I catabolism,
thereby attenuating reverse cholesterol transport (32). Post-
prandial lipemia may also contribute to atherogenesis (33).
Delayed clearance of TG-rich lipoproteins has been observed
in CAD patients (34) and may occur despite normal fasting TG
levels (35). Finally, hypertriglyceridemia may promote throm-
bogenicity owing to enhanced secretion of factor VII and
plasminogen activator inhibitor (36).
TG levels and CAD risk. In the present study, a threshold
effect for enhanced CAD risk was observed at TG levels ;100
mg/dl. This is noteworthy because an increased prevalence of
dense, more atherogenic LDL-C particles emerge as TG levels
exceed 100 mg/dl (31). That earlier studies stratified by TG
cutpoints of 200 mg/dl lacked the power to detect significant
differences in event rate may have reflected an inordinate
number of patients with considerably lower TG levels. Indeed,
extrapolation of previous published data have disclosed an
elevated risk of CAD when TG exceeds 100 mg/dl. In a 30-year
follow-up study of the Framingham Heart Study, the relative
risk of CAD was nearly twofold higher in men and women with
TG levels .250 mg/dl compared with ,100 mg/dl (37).
Similarly, in the Prospective Cardiovascular Munster Study of
4,221 patients followed up for 6 years, there was slightly
greater than twofold risk of CAD events within the highest
tertile of TG (.162 mg/dl) than with the lowest (,105 mg/dl)
(p , 0.001); the vast majority of patients in the study evidenced
TG levels ,200 mg/dl (mean TG levels with and without CAD
were 163 and 134.5 mg/dl, respectively) (38). Comparable
findings extended to patients with fasting hyperglycemia where
TG levels above the median (123 mg/dl) had a significant
impact on CAD mortality rates (39).
TG reduction and CAD event rate/arteriographic changes.
Although recent evidence ascribes a noteworthy role for TG in
assessing CAD risk, no studies have examined the impact of
selective TG reduction on the CAD event rate. In the Helsinki
Heart Study, patients with TG levels .200 mg/dl and a high
LDL-C/HDL-C ratio (.5) exhibited the greatest reduction in
CAD events with gemfibrozil (40). A trial evaluating bezafi-
brate on CAD progression in survivors of myocardial infarc-
tion found significantly reduced arteriographic progression in
association with reduced TG (31%) and fibrinogen (12%)
levels, despite only modest HDL-C elevation (9%) and no
significant reduction in LDL-C (41). More recently, gemfibro-
zil reduced TG levels 36% and retarded progression of saphe-
nous vein bypass graft lesions in normolipidemic men (mean
TG level ;150 mg/dl) with low HDL-C levels (42). An ongoing
secondary prevention study in normocholesterolemic patients
will assess the relative contribution of TG reduction (and
HDL-C raising) on cardiovascular end points (43).
Study limitations. Limitations of the present study include
lack of apolipoprotein B measurements, which were not rou-
tinely performed at the study’s outset. The measurement of the
apolipoprotein B particle number is important because of the
association between elevated TG levels and small, dense
LDL-C (44). Moreover, lipid and lipoprotein measurements
are variable and influenced by postprandial fat and factors
affecting rheology (45). Although only one fasting measure-
ment was performed in the present study, TG variability was
minimized by measuring levels in the fasting state (14 h) and
in the supine position before cardiac catheterization. In
addition, patients were eliminated from participation if 1)
blood was drawn after heparin was administered (heparin
activates lipoprotein lipase and may falsely lower TG) and
2) a myocardial infarction occurred within 3 months of the
study owing to artifically elevated TG elevation compared
with basal conditions (46). Finally, the study was performed
in patients admitted for diagnostic coronary arteriography.
As such, the level of TG at which CAD risk was found to
increase (100 mg/dl) may not be applicable to the popula-
tion at large.
Conclusions and potential implications. A recent case-
control study (47) supports the meta-analysis by Hokanson and
Austin (48) that TG independently predicts initial CAD events
even after adjustment for HDL-C. The present study extends
these observations to CAD patients with a “normal” TG level.
One potential implication would be further encouragement of
hygienic measures (e.g., weight loss and exercise) than pres-
ently advocated for CAD patients in whom TG levels are well
within the desirable range (e.g., 100 to 199 mg/dl). The utility
of pharmacologic therapy is presently under evaluation (43).
Notwithstanding, until randomized clinical trials demonstrate
an independent effect of TG reduction on CAD event rate, it
Figure 2. Kaplan-Meier survival analysis comparing patients with
CAD stratified by baseline TG level (100 mg/dl) at 1977 to 1978
coronary arteriography. Wilcoxon log-rank test indicates significant
differences in event-free survival between the groups (p 5 0.008).
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is unlikely that significant alterations in TG cutpoints and
therapeutic strategies will accompany future NCEP revisions.
We gratefully acknowledge the assistance of Nagmeh Tebyanian, MD and Justin
Martos for data collection.
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